A Study of ARQ 171 in Patients With Advanced Solid Tumors
NCT ID: NCT00398840
Last Updated: 2017-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
14 participants
INTERVENTIONAL
2006-11-30
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with advanced solid tumors, who are refractory to available therapy or for whom no standard systemic therapy exists, will be enrolled.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
NCT00612209
ARQ 197 in Subjects With Metastatic Solid Tumors
NCT00302172
A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
NCT00609921
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
NCT00827177
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
NCT00612703
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ARQ 171
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A histologically or cytologically confirmed advanced solid tumor
* ≥ 18 years of age
* Measurable disease as defined by Response Evaluation Criteria in Solid Tumors
* Karnofsky performance status ≥ 70%
* Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after participation.
* Females of childbearing potential must have a negative serum pregnancy test.
* Laboratory results must meet study criteria.
Exclusion Criteria
* Surgery within 4 weeks prior to first infusion
* Known untreated brain metastases
* Pregnant or breastfeeding
* Uncontrolled intercurrent illness, or uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
* Other cancer within the last five years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arqule, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Premiere Oncology
Santa Monica, California, United States
Dana Farber/Harvard Cancer Center
Boston, Massachusetts, United States
Mary Crowley Medical Research Center
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ARQ 171-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.